Fintel reports that on December 8, 2025, BTIG reiterated coverage of Rapport Therapeutics (NasdaqGM:RAPP) with a Buy recommendation.
Analyst Price Forecast Suggests 78.07% Upside
As of December 6, 2025, the average one-year price target for Rapport Therapeutics is $52.53/share. The forecasts range from a low of $34.34 to a high of $84.00. The average price target represents an increase of 78.07% from its latest reported closing price of $29.50 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual non-GAAP EPS is -2.90.
What is the Fund Sentiment?
There are 237 funds or institutions reporting positions in Rapport Therapeutics. This is an increase of 29 owner(s) or 13.94% in the last quarter. Average portfolio weight of all funds dedicated to RAPP is 0.59%, an increase of 22.43%. Total shares owned by institutions increased in the last three months by 26.42% to 51,509K shares. 
The put/call ratio of RAPP is 0.39, indicating a bullish outlook.
What are Other Shareholders Doing?
Trv Gp V holds 7,135K shares representing 14.97% ownership of the company. No change in the last quarter.
Arch Venture holds 3,729K shares representing 7.82% ownership of the company. No change in the last quarter.
Capital International Investors holds 3,403K shares representing 7.14% ownership of the company. In its prior filing, the firm reported owning 2,603K shares , representing an increase of 23.51%. The firm increased its portfolio allocation in RAPP by 220.10% over the last quarter.
Cormorant Asset Management holds 3,193K shares representing 6.70% ownership of the company. In its prior filing, the firm reported owning 2,941K shares , representing an increase of 7.88%. The firm increased its portfolio allocation in RAPP by 162.67% over the last quarter.
Goldman Sachs Group holds 2,422K shares representing 5.08% ownership of the company. In its prior filing, the firm reported owning 1,235K shares , representing an increase of 49.01%. The firm increased its portfolio allocation in RAPP by 8.17% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
